BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24989305)

  • 1. [TET2 gene in hematological diseases].
    Li S; Wang XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):836-41. PubMed ID: 24989305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutation of tet2 gene and malignant blood disease].
    Qian XF; Shen YF; Zhang SJ; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [TET2 as a gatekeeper for hematologic malignancies].
    Muto H; Sakata-Yanagimoto M; Chiba S
    Rinsho Ketsueki; 2015 Jun; 56(6):651-6. PubMed ID: 26256875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
    Nakajima H; Kunimoto H
    Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
    Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-Associated
    Ferrone CK; Blydt-Hansen M; Rauh MJ
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
    Ito K; Lee J; Chrysanthou S; Zhao Y; Josephs K; Sato H; Teruya-Feldstein J; Zheng D; Dawlaty MM; Ito K
    Cell Rep; 2019 Sep; 28(10):2480-2490.e4. PubMed ID: 31484061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The TET2 interactors and their links to hematological malignancies.
    Pan F; Weeks O; Yang FC; Xu M
    IUBMB Life; 2015 Jun; 67(6):438-45. PubMed ID: 26099018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time.
    Flores JC; Ito K; Huang CY; Tang Q; Yanase C; Ito K; Dawlaty MM
    Exp Hematol; 2023 Aug; 124():45-55.e2. PubMed ID: 37225048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.
    Li Z; Cai X; Cai CL; Wang J; Zhang W; Petersen BE; Yang FC; Xu M
    Blood; 2011 Oct; 118(17):4509-18. PubMed ID: 21803851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies.
    Li R; Xu MJ; Yang FC; Zhou Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Oct; 38(5):583-588. PubMed ID: 27825418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.
    Tefferi A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Patnaik MM; Hanson CA; Pardanani A; Gilliland DG; Levine RL
    Leukemia; 2009 Jul; 23(7):1343-5. PubMed ID: 19295549
    [No Abstract]   [Full Text] [Related]  

  • 16. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
    Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M; Huang Y; Jankowska AM; Pape UJ; Tahiliani M; Bandukwala HS; An J; Lamperti ED; Koh KP; Ganetzky R; Liu XS; Aravind L; Agarwal S; Maciejewski JP; Rao A
    Nature; 2010 Dec; 468(7325):839-43. PubMed ID: 21057493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms.
    Seethy AA; Pethusamy K; Kushwaha T; Kumar G; Talukdar J; Chaubey R; Sundaram UD; Mahapatra M; Saxena R; Dhar R; Inampudi KK; Karmakar S
    BMC Cancer; 2023 Oct; 23(1):1035. PubMed ID: 37884893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.